Filing Details
- Accession Number:
- 0001178913-20-002210
- Form Type:
- 13G Filing
- Publication Date:
- 2020-08-03 08:39:21
- Filed By:
- Aurum Ventures M.k.i. Ltd.
- Company:
- Notable Labs Ltd.
- Filing Date:
- 2020-08-03
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Aurum Ventures M.K.I. Ltd | 6,839,059 | 0 | 6,839,059 | 0 | 6,839,059 | 13.9% |
| Morris Kahn | 0 | 6,839,059 | 0 | 6,839,059 | 6,839,059 | 13.9% |
Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
SCHEDULE 13G/A
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO § 240.13d-2
(Amendment No. 2)*
Vascular Biogenics Ltd.
(Name of Issuer)
Ordinary Shares, par value NIS 0.01
(Title of Class of Securities)
M96883109
(CUSIP Number)
Ilan Lior
General Counsel
Aurum Group
16 Abba Hillel Road
Ramat Gan 5250608, Israel
Tel +972-3-576-2424
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 12, 2020
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☒ | Rule 13d-1(c) |
| ☐ | Rule 13d-1(d) |
* The remainder of this cover page shall be
filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
| CUSIP No. M96883109 | 13G/A | Page 2 of 7 Pages |
| 1. | NAMES OF REPORTING PERSONS Aurum Ventures M.K.I. Ltd. | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ☐ (b) ☐ | ||
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Israel | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 6,839,059 (1) | |
| 6. | SHARED VOTING POWER 0 | ||
| 7. | SOLE DISPOSITIVE POWER 6,839,059 (1) | ||
| 8. | SHARED DISPOSITIVE POWER 0 | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,839,059 (1) | ||
| 10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see
instructions) ☐ | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 13.9% (2) | ||
| 12. | TYPE OF REPORTING PERSON (see instructions) CO | ||
| (1) | Includes 1,269,841 Ordinary Shares that underlie warrants to purchase Ordinary Shares that are held by the Reporting Person and that are currently exercisable. |
| (2) | Percentage is based on 47,896,736 Ordinary Shares of the Issuer that were issued and outstanding as of May 27, 2020, as set forth in the Issuer’s registration statement on Form F-1, filed with the Securities and Exchange Commission (the “SEC”) on June 1, 2020, as adjusted upwards to include an additional 1,269,841 Ordinary Shares that underlie warrants held by the Reporting Person that are currently exercisable. |
| CUSIP No. M96883109 | 13G/A | Page 3 of 7 Pages |
| 1. | NAMES OF REPORTING PERSONS Morris Kahn | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ☐ (b) ☐ | ||
| 3. | SEC USE ONLY | ||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Israel | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
| 6. | SHARED VOTING POWER 6,839,059 (1) | ||
| 7. | SOLE DISPOSITIVE POWER 0 | ||
| 8. | SHARED DISPOSITIVE POWER 6,839,059 (1) | ||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,839,059 (1) | ||
| 10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see
instructions) ☐ | ||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 13.9% (2) | ||
| 12. | TYPE OF REPORTING PERSON (see instructions) IN | ||
| (1) | Includes 1,269,841 Ordinary Shares that underlie warrants to purchase Ordinary Shares that are held by Aurum Ventures M.K.I.
Ltd. (with respect to which the Reporting Person shares voting and dispositive power) and that are currently exercisable. |
| (2) | Percentage is based on 47,896,736 Ordinary Shares of the Issuer that were issued and outstanding as of May 27, 2020, as set forth in the Issuer’s registration statement on Form F-1, filed with the SEC on June 1, 2020, as adjusted upwards to include an additional 1,269,841 Ordinary Shares that underlie warrants held by Aurum Ventures M.K.I. Ltd. (with respect to which the Reporting Person shares voting and dispositive power)
and that are currently exercisable. |
Item 1.
| (a) | Name of Issuer Vascular Biogenics Ltd. |
| (b) | Address of Issuer’s Principal Executive Offices 8 HaSatat St. Modi’in, Israel 7178106 |
Item 2.
| (a) | Name of Person Filing: This Amendment No. 2 (this “Amendment No. 2”) to the Statement of Beneficial Ownership on Schedule 13G that was
filed on February 17, 2015 (the “Statement”), as amended by Amendment No. 1 thereto, filed on February 13, 2020 (“Amendment No. 1”), is being filed by each of: (i) Aurum Ventures M.K.I. Ltd. (the “Reporting Entity”) (ii) Morris Kahn (the “Reporting Individual”) The Reporting Individual is the sole beneficial shareholder of the Reporting Entity. The Reporting Entity and the Reporting Individual are referred
to herein collectively as the “Reporting Persons”. This Amendment No. 2 reports the acquisition, by the Reporting Persons, since the filing of Amendment No. 1, of beneficial
ownership over an additional 1,269,841 Ordinary Shares and an additional 1,269,841 Ordinary Shares underlying warrants to purchase Ordinary Shares (all of which warrants are currently exercisable), which were acquired by the Reporting
Entity in a public offering that was consummated by the Issuer on May 12, 2020. |
| (b) | Address of Principal Business Office or, if None, Residence: The principal business office of each of the Reporting Persons is c/o Aurum Group, 16 Abba Hillel Road Ramat Gan 5250608, Israel |
| (c) | Citizenship: The Reporting Entity is organized in Israel. The Reporting Individual is a citizen of the State of Israel. |
| (d) | Title of Class of Securities Ordinary Shares, New Israeli Shekel (“NIS”) 0.01 par value
per share (“Ordinary Shares”) |
| (e) | CUSIP Number M96883109 |
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the
person filing is a:
| (a) | ☐ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
| (b) | ☐ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
| (c) | ☐ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). |
| (d) | ☐ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
| (e) | ☐ | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
| (f) | ☐ | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
| (g) | ☐ | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); |
| (h) | ☐ | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | ☐ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3); |
| (j) | ☐ | Group, in accordance with §240.13d-1(b)(1)(ii)(J). |
Not applicable.
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer
identified in Item 1.
With respect to each of the Reporting Persons:
| (a) | Amount beneficially owned: 6,839,059 Ordinary Shares (consisting of 5,569,218 Ordinary Shares and 1,269,841
additional Ordinary Shares underlying warrants to purchase Ordinary Shares that are currently exercisable) | |||
| (b) | Percent of class: 13.9%* *Such percentage is based on 47,896,736 Ordinary Shares of the Issuer that were issued and outstanding as of May 27, 2020, as set forth in the Issuer’s registration statement
on Form F-1, filed with the Securities and Exchange Commission on June 1, 2020, as adjusted upwards to include an additional 1,269,841 Ordinary Shares that underlie currently-exercisable warrants held by the Reporting Entity (with respect to which the Reporting
Person shares voting and dispositive power). | |||
| (c) | Number of shares as to which the person has: | |||
| (i) | Sole power to vote or to direct
the vote: Reporting Entity: 6,839,059 Reporting Individual: 0 | |||
| (ii) | Shared power to vote or to direct
the vote: Reporting Entity: 0 Reporting Individual: 6,839,059 | |||
| (iii) | Sole power to dispose or to
direct the disposition of: Reporting Entity: 6,839,059 Reporting Individual: 0 | |||
| (iv) | Shared power to dispose or to
direct the disposition of: Reporting Entity: 0 Reporting Individual: 6,839,059 | |||
By way of his beneficial
ownership of all outstanding shares of the Reporting Entity, the Reporting Individual exercises shared voting and dispositive power with respect to all 6,839,059
Ordinary Shares that are beneficially owned by the Reporting Entity and that are reported in this Amendment No. 2.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of securities, check the following ☐.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the
proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of
an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on By the Parent Holding Company.
If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under
Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating
the identification of the relevant subsidiary.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(K), so indicate under Item 3(k) and attach an exhibit
stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further
filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. (See Item 5)
Not applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that
purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this
statement is true, complete and correct.
| AURUM VENTURES M.K.I. LTD. By: /s/ Nir Dror-Darwish Name:Nir Dror-Darwish Title: Authorized Signatory
By: /s/ Ilan Lior Name: Ilan Lior Title: Authorized Signatory
Date: August 3, 2020 /s/ Morris Kahn MORRIS KAHN Date: August 3, 2020 |